Kos BioVentures, the inaugural fund of Kos, backed Golden Age Health (GAH) with an investment intended to expand commercial reach across Greater China and wider APAC. The partnership is framed around improving patient access to approved and near-approved therapies, including regulatory and market-access services. Kos said the allocation also complements its early-stage discovery portfolio by building a distribution and launch pathway for Western assets into complex Asian markets. Financial terms were not disclosed, but the fund’s context—Kos BioVentures’ third closing—signals a deliberate move into the access side of biopharma commercialization.